Fig 1.
Flowchart of the research process.
This includes data collection, identification of chromatin epigenetic-related lncRNA signatures, clinical data validation, prognostic prediction, and immunotherapy prediction.
Fig 2.
Prognostic prediction based on the identified lncRNA signature (CELncSig).
(A) Patients in the low-risk group showed longer overall survival (OS) in the Kaplan-Meier analysis. (B, C) Survival status and risk scores for each sample. (D) Heatmap shows the expression of CELncSigs, with blue indicating low expression and red indicating high expression.
Fig 3.
Validation of the prognostic prediction.
(A, B) Calibration curves show the consistency between predicted and observed OS. (C-N) Kaplan-Meier OS curves of subgroups stratified by clinical factors, including AJCC stages (C-E), age (F, G), race (H, I), T stage (J-L), gender (M, N), M stage (O), and N stage (P-R).
Fig 4.
GO and KEGG pathway analysis of the differentially expressed lncRNAs between high- and low-risk groups.
(A, B) GO enrichment analysis. (C, D) KEGG enrichment analysis.
Fig 5.
Tumor immune escape analysis of the cohorts.
Comparison of CD274, CD8, TIDE, Dysfunction, and Exclusion scores between high- and low-risk groups in the (A-E) training, (F-J) validation, and (K-O) all cohorts. "*" means P value<0.05, "**" means P value<0.01, "***" means P value<0.001. "ns" means no significance.
Fig 6.
Tumor immune escape analysis of the cohorts.
Comparison of IFNG, MDSC, and CAFs scores between high- and low-risk groups in the training, validation, and all cohorts. "*" means that P value<0.05, "**" means that P value<0.01, "***" means that P value<0.001. "ns" means no significance.
Fig 7.
Prediction of differential chemotherapy drug sensitivity between high- and low-Risk groups.
CMK, Bortezomib, Bryostatin 1, Docetaxel, Doxorubicin, Elesclomol, MS275, MK2206, Methotrexate, and Lenalidomide showed higher sensitivity in the low-risk group. CMK, Bortezomib, Bryostatin 1, Docetaxel, Doxorubicin, Elesclomol, and MS275 showed higher sensitivity in the high-risk group.